Search
Ponatinib
go.drugbank.com/drugs/DB08901ApprovedInvestigationalPonatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.
Rimantadine
go.drugbank.com/drugs/DB00478ApprovedAn RNA synthesis inhibitor that is used as an antiviral agent in the prophylaxis and treatment of influenza.
Tabelecleucel
go.drugbank.com/drugs/DB17072ApprovedInvestigationalBoth T-cells and B-cells are obtained from the same donor, and T-cells are grown to increase their numbers. … It is produced by mixing T-cells with B-cells that have been infected with the Epstein-Barr virus (EBV).
Dorzolamide
go.drugbank.com/drugs/DB00869ApprovedInvestigational[L11377] It works by blocking an enzyme in the ciliary process that regulates ion balance and fluid pressure in the eyes.
Biperiden
go.drugbank.com/drugs/DB00810ApprovedInvestigationalWithdrawnIt has also been used to alleviate extrapyramidal symptoms induced by phenothiazine derivatives and reserpine.
Fibrinogen human
go.drugbank.com/drugs/DB09222ApprovedInvestigationalIt works by replacing a specific protein in the blood, fibrinogen (factor I), that helps with blood clotting.
AGRO100
go.drugbank.com/drugs/DB04998InvestigationalAGRO100 is an oligonucleotide that functions as an aptamer and binds to nucleolin, a protein found intranuclear in all cells, but uniquely expressed on the surface of tumor cells.
Equine Botulinum Neurotoxin E Immune FAB2
go.drugbank.com/drugs/DB13897ApprovedEquine Botulinum Neurotoxin E Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype E.
Equine Botulinum Neurotoxin C Immune FAB2
go.drugbank.com/drugs/DB13898ApprovedEquine Botulinum Neurotoxin C Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype C.
Human papillomavirus type 52 L1 capsid protein antigen
go.drugbank.com/drugs/DB10313ApprovedInvestigationalIt is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) type 52 The vaccine is prepared from the purified virus-like particles … (VLPs) of the major capsid (L1) protein of HPV Type 52 which are produced by separate fermentations in recombinant *Saccharomyces cerevisiae* and self-assembled into VLPs.